The FDA said Tuesday that shortages of three higher doses of Eli Lilly’s type 2 diabetes drug Mounjaro aren’t expected to ease until May, and another lower dose is now in short supply as well.
According to the FDA’s website, the 7.5, 10.0, 12.5, and 15.0 mg doses of Mounjaro will have “limited availability” through April due to increased demand. In February, the regulator said there would be supply issues for the three higher doses through early March.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.